US2019142845A1PendingUtilityA1
Anticonvulsant activity of steroids
Est. expiryNov 30, 2032(~6.3 yrs left)· nominal 20-yr term from priority
A61P 25/32A61P 25/08A61P 25/24A61P 25/34A61P 25/28A61P 25/22A61P 25/00A61K 31/573A61K 9/08A61K 31/56A61K 9/0019A61K 31/57A61K 47/40
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to methods of preventing, inhibiting, delaying, and/or mitigating seizures by administration of a steroid, e.g., a neurosteroid, e.g., allopregnanolone.
Claims
exact text as granted — not AI-modified1 .- 21 . (canceled)
22 . A composition comprising or consisting essentially of a steroid and a cyclodextrin.
23 . The composition of claim 22 , wherein the steroid is a neurosteroid.
24 . The composition of claim 23 , wherein the neurosteroid is selected from the group consisting of allopregnanolone, allotetrahydrodeoxycorticosterone, ganaxolone, alphaxolone, alphadolone, hydroxydione, minaxolone, and Althesin.
25 . The composition of any one of claims 22 to 24 , wherein the steroid is allopregnanolone.
26 . The composition of any one of claims 22 to 25 , wherein the cyclodextrin is hydroxypropyl-beta-cyclodextrin, sulfobutylether-beta-cyclodextrin sodium salt, or a mixture thereof.
27 . The composition of any one of claims 22 to 26 , wherein the composition is formulated for intramuscular (i.m.), subcutaneous (s.c.) or intravenous (i.v.) administration.
28 . The composition of any one of claims 22 to 27 , wherein the composition comprises allopregnanolone and sulfobutylether-beta-cyclodextrin sodium salt.Join the waitlist — get patent alerts
Track US2019142845A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.